NFE2L2 and lung cancer: Prior studies have also shown that lung cancer cells harboring KRAS mutations reprograms cancer cell metabolite towards glutamine dependence through NRF2-mediated signaling activities that increase expression of enzymes involved in glutaminolysis [16,17,18].